An interventional study of Infliximab and Mercaptopurine in Inflammatory Bowel Diseases, sponsored by University Hospital, Lille. Terminated at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-02-15.
Sponsored by University Hospital, Lille · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Inflammatory Bowel Diseases by University Hospital, Lille — 1 open to participants now, 1 under way, none of them phase 3. Inflammatory Bowel Diseases · University Hospital, Lille.
Among the 10 studies in Inflammatory Bowel Diseases by University Hospital, Lille, this one is the only one that started in 2017, is one of 4 with no phase, and was the 4th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 424 are open to participants now.
Browse Inflammatory Bowel Diseases studies →1 of the 10 studies in Inflammatory Bowel Diseases by University Hospital, Lille is open now, in 1 country. Recruiting first, the newest first:
University Hospital, Lille · Sites in France
Ages 25–60 · Healthy volunteers
By country, each count listing its studies:
Of the 277 Inflammatory Bowel Diseases studies recruiting now, 134 (48%) set no upper age limit and 115 (42%) stop at 75 or younger; 76 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2017.
This study's enrollment of 9 is below the median of 68 across 873 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 40 across the 4 interventional studies, 119 across the 6 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Inflammatory Bowel Diseases by University Hospital, Lille, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates 2 therapeutic strategies (increase infliximab dose or add an immunosuppressant) in patients with inflammatory bowel disease in loss of response to infliximab. Addition of an immunosuppressant may be more efficient at long term and is less expensive.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
increase of Infliximab dose from 5mg/kg every 8 weeks to Infliximab 10 mg/kg every 8 weeks
Drug: Infliximab
same dose of Infliximab ( 5mg/kg every 8 weeks) with addition of immunosuppressive agent: Azathioprine or Mercaptopurine
Drug: Mercaptopurine · Drug: Azathioprine · Drug: Infliximab
Infliximab 10mg/kg every 8 weeks
6-mercaptopurine 1 à 1,5 mg/kg
Also known as: addition strategy with 6-mercaptopurine in second intention
Azathioprine 2 à 2.5mg/kg/j
Also known as: addition strategy with azathioprine in first intention
Infliximab 5mg/kg every 8 weeks
Number of patients in Clinical remission
the clinical remission is defined by Harvey Bradshaw (HBI) Index \< 4 for Crohn's disease or Simple Clinical Colitis Activity Index (SCCAI)\<4 for ulcerative colitis.
Time frame: At Week 52
Number of patients in deep remission
clinical remission associated with endoscopic remission (CDEIS \<3 for CD patients or Mayo score\<2 for UC patients)
Time frame: At Week 52
Number of patient in remission and clinical response
clinical response is defined as a decrease of at least 3 points of HBI for CD patients or SCCAI for UC patients compared to baseline (week 0). Simple Clinical Colitis Activity Index (SCCAI)\<4 for ulcerative colitisHBI pour MC et SCCAI pour RCH \<4 associated at CRP \< 5 mg/dl.
Time frame: At week 16
infliximab blood concentration
Time frame: Baseline, week 16 ad week 52
infliximab antibodies concentration
Time frame: Baseline, week 16 ad week 52
economic criteria
medical fees in each arm
Time frame: At week 52
number of patient with adverse effects and allergic reactions with infliximab
Time frame: At week 52
Inflammatory bowel disease questionnaire (score IBDQ)
quality of life
Time frame: Baseline and week 52
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2017 to primary completion in Jan 2019, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.